141836-50-2

Usage

Uses

Used in Pharmaceutical Industry:
[4-(tert-Butyldimethylsilyloxymethyl)cyclohexyl]methanol is used as an intermediate in the production of Rho kinase inhibitors for the pharmaceutical industry. Rho kinase inhibitors are important in the treatment of various diseases, including cardiovascular and neurological disorders, by modulating the activity of Rho-associated protein kinase.
Used in Neurochemistry Research:
In the field of neurochemistry, [4-(tert-Butyldimethylsilyloxymethyl)cyclohexyl]methanol is used as an intermediate for the synthesis of neurite outgrowth promoters. These compounds play a crucial role in the development and maintenance of the nervous system, as they help in the growth and extension of nerve cells, which is essential for proper neuronal function and communication.
Used in Chemical Synthesis:
As a colorless oil with specific functional groups, [4-(tert-Butyldimethylsilyloxymethyl)cyclohexyl]methanol can also be utilized in various chemical synthesis processes across different industries. Its unique structure allows it to serve as a versatile building block for creating a wide range of compounds with diverse applications.

Upstream product

• 105-08-8 bis-1,4-(hydroxymethyl)cyclohexane 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 124-38-9 carbon dioxide 
• 13380-84-2 4-(hydroxymethyl)cyclohexane-1-carboxylic acid 

Downstream Products

• 141836-47-7 4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexane carbaldehyde 
• 129830-38-2 (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide dihydrochloride 
• 672314-62-4 (R)-N-tert-butyloxycarbonyl-1-[4'-(hydroxymethyl)cyclohexyl]ethan-1-amine 
• 672314-63-5 (S)-N-tert-butyloxycarbonyl-1-[4'-(hydroxymethyl)cyclohexyl]ethan-1-amine 
• 672314-52-2 (S)-1-[4-(tert-butyldimethylsilyloxymethyl)cyclohexyl]ethan-1-amine 
• 672314-51-1 (R)-1-[4-(tert-butyldimethylsilyloxymethyl)cyclohexyl]ethan-1-amine 
• 672314-40-8 (R)-N-[(4'-tert-butyldimethylsilyloxymethyl-cyclohexyl)methylidene]-1-phenylethanamine 
• 672314-41-9 (S)-N-[(4'-tert-butyldimethylsilyloxymethyl-cyclohexyl)methylidene]-1-phenylethanamine 
• 672314-59-9 (S)-N-tert-butyloxycarbonyl-1-[4'-(tert-butyldimethylsilyloxymethyl)cyclohexyl]ethan-1-amine 
• 672314-58-8 (R)-N-tert-butyloxycarbonyl-1-[4'-(tert-butyldimethylsilyloxymethyl)cyclohexyl]ethan-1-amine 

Relevant academic research and scientific papers

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

IMIDAZOLE COMPOUND

Disclosed is an imidazole compound, in particular, the compound as shown in formula (I) and a pharmaceutically acceptable salt or tautomer thereof are disclosed.

SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF

The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

Facile cleavage of silyl protecting groups with catalytic amounts of FeCl3

A very mild and environmentally benign method for removal of silyl protecting groups using catalytic amounts of iron ion in MeOH is presented. The method is particularly effective for cleaving triethylsilyl (TES) protecting groups. Georg Thieme Verlag Stuttgart.

Synthesis and evaluation of 4-(1-aminoalkyl)-N-(4-pyridyl) cyclohexanecarboxamides as Rho kinase inhibitors and neurite outgrowth promoters

The influence of stereochemistry and alkyl side chain length on the bioactivity of the Rho kinase inhibitor Y-27632 [(+)-1, R = Me] was examined by the synthesis of (+)- and (-)-1, and two alkyl chain analogs (+)- and (-)-2 (R = n-propyl) and (-)-3 (R = n

1,4-SUBSTITUTED CYCLOHEXANE DERIVATIVES

Allylic compounds represented by the formula (I) are provided, wherein each of R1 to R8, m, n, A and X are as defined in the Specification. These compounds can inhibit Rho kinase, and can find utility in repair of damaged nerves in the central and peripheral nervous system by inducing axon growth and regeneration, and in the treatment by inhibition of Rho kinase in disease states in which Rho kinase is implicated. The compounds are relatively cell permeable and pharmaceutical compositions thereof can promote neurite growth and are also useful for the prevention of cell proliferation in malignant deseases.

Substituted cyclohexane derivatives

The present invention relates to compounds of formula (I) wherein A1, A2, A3, A4, A5, A6, U, V, m, n and o are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the 2,3-oxidosqualene-lanosterol cyclase biosynthetic pathway such as hypercholesterolemia and hyperlipemia.

Substituted cyclohexane derivatives

The present invention provides compounds of formula (I) wherein A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, U, V, W, m, n and p are as indicated in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia and hyperlipemia.

Selective deprotection of t-butyldiphenylsilyl ethers in the presence of t-butyldimethylsilyl ethers by tetrabutylammonium fluoride, acetic acid, and water

The selective deprotection of t-butyldiphenylsilyl ethers in the presence of t-butyldimethylsilyl ethers by tetrabutylammonium fluoride, acetic acid, and water has been realize.